Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01468181
First received: November 7, 2011
Last updated: January 16, 2015
Last verified: January 2015

November 7, 2011
January 16, 2015
November 2011
December 2013   (final data collection date for primary outcome measure)
  • Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Baseline through 52 Weeks ] [ Designated as safety issue: Yes ]
    A TEAE was defined as an event that first occurs or worsens (increases in severity) after baseline, regardless of causality or severity. The percentage of participants with TEAEs was calculated by dividing the number of participants with at least 1 TEAE over the 52-week treatment period by the total number of participants analyzed, multiplied by 100%. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
  • Percentage of Participants With Hypoglycemic Episodes [ Time Frame: Baseline through 52 Weeks ] [ Designated as safety issue: Yes ]
    The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least 1 hypoglycemic episode over the 52-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
  • Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Baseline through 52 Weeks ] [ Designated as safety issue: Yes ]
  • Percentage of Participants with Hypoglycemic Episodes [ Time Frame: Baseline through 52 Weeks ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01468181 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline, up to 26 Weeks and up to 52 Weeks ] [ Designated as safety issue: No ]
  • Percentage of Participants Who Achieve HbA1c ≤6.5% or <7% [ Time Frame: 26 weeks and 52 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Fasting Blood Glucose (FBG) [ Time Frame: Baseline, up to 26 weeks and up to 52 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) [ Time Frame: Baseline, up to 26 weeks and up to 52 weeks ] [ Designated as safety issue: No ]
    Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal. For the mean of all 7-point blood glucose values, the daily mean was calculated as the average of 7 blood glucose values collected on a particular day. The mean of all 7-point blood glucose values at each visit was calculated as the average of 2 daily means. The change from baseline was calculated as the mean of all 7-point blood glucose values at endpoint minus the mean of all 7-point blood glucose values at baseline.
  • Change From Baseline in Body Weight [ Time Frame: Baseline, up to 26 weeks and up to 52 weeks ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Updated Homeostasis Model Assessment (HOMA2) [ Time Frame: Baseline, up to 26 weeks and up to 52 weeks ] [ Designated as safety issue: No ]
    The HOMA2 is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state pancreatic beta cell function (%B) and to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. The change from baseline for fasting insulin concentrations are presented as insulin secretion (HOMA2-%B) and insulin sensitivity (HOMA2-%S).
  • Change from Baseline in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline, 26 weeks, 52 weeks ] [ Designated as safety issue: Yes ]
  • Percentage of Participants Who Achieve HbA1c <=6.5% or <7% [ Time Frame: 26 weeks and 52 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Fasting Blood Glucose (FBG) [ Time Frame: Baseline, 26 weeks, 52 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) [ Time Frame: Baseline, 26 weeks, 52 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Body Weight [ Time Frame: Baseline, 26 weeks, 52 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Updated Homeostasis Model Assessment (HOMA 2) [ Time Frame: Baseline, 26 weeks, 52 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus

This was a 52-week, multicenter, non-randomized, open-label, Phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication (OAM).

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: LY2189265
    Other Name: Dulaglutide
  • Drug: Sulfonylureas (SU)
    SU is a pre-study prescribed dose and is not being provided as part of the trial.
  • Drug: Biguanides (BG)
    Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
  • Drug: alpha-glucosidase inhibitor (a-GI)
    a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
  • Drug: Thiazolidinedione (TZD)
    TZD is a pre-study prescribed dose and is not being provided as part of the trial.
  • Drug: Glinides
    Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
  • Experimental: LY2189265 + Sulfonylureas (SU)

    LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks

    Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study.

    Interventions:
    • Drug: LY2189265
    • Drug: Sulfonylureas (SU)
  • Experimental: LY2189265 + Biguanides (BG)

    LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

    Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study.

    Interventions:
    • Drug: LY2189265
    • Drug: Biguanides (BG)
  • Experimental: LY2189265 + alpha-glucosidase inhibitor (a-GI)

    LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

    Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study.

    Interventions:
    • Drug: LY2189265
    • Drug: alpha-glucosidase inhibitor (a-GI)
  • Experimental: LY2189265 + Thiazolidinedione (TZD)

    LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

    Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study.

    Interventions:
    • Drug: LY2189265
    • Drug: Thiazolidinedione (TZD)
  • Experimental: LY2189265 + Glinides

    LY2189265: 0.75 mg administered SC, once weekly for 52 weeks

    Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study.

    Interventions:
    • Drug: LY2189265
    • Drug: Glinides
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
394
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants who have had a diagnosis of type 2 diabetes mellitus before screening
  • Participants who have been taking SU (Glibenclamide, Gliclazide, Glimepiride), BG, TZD, a-GI or glinides monotherapy for at least 3 months before screening and have been on a stable dose for at least 8 weeks before screening
  • Participants must have a qualifying HbA1c value of 7.0% to 11.0% at screening
  • Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m^2)

Exclusion Criteria:

  • Participants who have a diagnosis of type 1 diabetes
  • Participants who have previously been treated with any other glucagon-like peptide-1 (GLP-1) analog within the 3 months before screening
  • Participants who are currently taking insulin or have had previous insulin treatment within the 3 months before screening
  • Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥3 times the upper limit of the reference range and/or a serum lipase concentration ≥2 times the upper limit of the reference range, as determined by the central laboratory at screening
  • Participants who have self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC)
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01468181
13991, H9X-JE-GBDQ
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time (UTC/GMT - 5, hours, EST) Eli Lilly and Company
Eli Lilly and Company
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP